摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-苯基-1H-苯并[D][1,3]恶嗪-2,4-二酮 | 20877-86-5

中文名称
1-苯基-1H-苯并[D][1,3]恶嗪-2,4-二酮
中文别名
——
英文名称
N-phenyl isatoic anhydride
英文别名
1-phenyl-2H-benzo[d][1,3]oxazine-2,4(1H)-dione;N-Phenylisatinsaeureanhydrid;N-Phenyl-isatosaeure-anhydrid;1-Phenyl-1H-benzo[d][1,3]oxazine-2,4-dione;1-phenyl-3,1-benzoxazine-2,4-dione
1-苯基-1H-苯并[D][1,3]恶嗪-2,4-二酮化学式
CAS
20877-86-5
化学式
C14H9NO3
mdl
——
分子量
239.23
InChiKey
JXLXUQZYJCFIGY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    18
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    46.6
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090

SDS

SDS:4c40bbf119fad333c5029fe89f691ac7
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-苯基-1H-苯并[D][1,3]恶嗪-2,4-二酮 在 sodium tetrahydroborate 作用下, 以 四氢呋喃 为溶剂, 以74%的产率得到(2-苯胺基苯基)甲醇
    参考文献:
    名称:
    2 H -3,1-苯并恶嗪-2,4(1 H)-二酮(异戊酸酐)的化学性质。19 †。由N-取代的等角酸酐的还原反应直接形成2-氨基苄醇
    摘要:
    用硼氢化钠容易地将Isatoic酸酐1良好地还原为邻(取代的氨基)苄醇3。用硼氢化钠顺序还原N-(2-硝基苄基)乙酸酐(5),然后催化氢化硝基,以72%的收率得到天然存在的2-(2'-氨基苄基氨基)-苄醇(4)。
    DOI:
    10.1002/jhet.5570230145
  • 作为产物:
    描述:
    参考文献:
    名称:
    Coppola, Gary M., Journal of Heterocyclic Chemistry, 1987, vol. 24, p. 1249 - 1251
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Synthesis of Ring-Fused, N-Substituted 4-Quinolinones Using p<i>K</i><sub>a</sub>-Guided, Base-Promoted Annulations with Isatoic Anhydrides: Total Synthesis of Penicinotam
    作者:Muhammad M. Khalifa、Satish Chandra Philkhana、Jennifer E. Golden
    DOI:10.1021/acs.joc.9b02541
    日期:2020.1.17
    deprotonation susceptibility, such as tetramic and tetronic acids, cyclic 1,3-diketones, and cycloalkanones. Application to the synthesis of bioactive, pyrrolizine-fused 4-quinolinone, penicinotam 3, resulted in the most brief and highest yielding total synthesis of the alkaloid in three steps and a 36% overall yield.
    开发了一种使用等位酸酐和多种可烯化伙伴的阴离子环化策略,以提供80多种新型的环稠合N取代的4-喹啉酮,这是一种代表性不足的特权模板。确定了控制转化效率的多种因素,从而形成了可靠且可调谐的合成平台,适用于具有多种去质子化敏感性的多种底物,例如四甲酸和四氢代酸,环状1,3-二酮和环烷酮。应用于生物活性的吡咯烷嗪融合的4-喹啉酮青霉素3的合成中,生物碱的合成过程最简单,最高,分三步进行,总产率为36%。
  • Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 2-oxo-4-chloro-1,2-dihydroquinoline-3-carboxamide moiety
    作者:Qidong Tang、Xin Zhai、Yayi Tu、Ping Wang、Linxiao Wang、Chunjiang Wu、Wenhui Wang、Hongbo Xie、Ping Gong、Pengwu Zheng
    DOI:10.1016/j.bmcl.2016.02.037
    日期:2016.4
    A series of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 2-oxo-4-chloro-1,2-dihydroquinoline-3-carboxamide moiety were synthesized, and evaluated for their antiproliferative activity against 5 cancer cell lines (H460, HT-29, MKN-45, A549, and U87MG). Most compounds showed moderate to excellent potency, and compared to foretinib, the most promising analog 42 (c-Met/Flt-3 IC50 = 1.21/2
    合成了一系列带有2-oxo-4-chloro-1,2,dihydroquinoline-3-carboxamide部分的6,7-di取代-4-phenoxyquinoline衍生物,并评估了它们对5种癌细胞系(H460, HT-29,MKN-45,A549和U87MG)。大多数化合物显示出中等至出色的效力,并且与foretinib相比,最有前途的类似物42(c-Met / Flt-3 IC 50  = 1.21 / 2.15 nM)在体外对H460细胞系的活性提高了6.1倍。在体外评估了化合物42的酶促测定(c-Met,VEGFR-2,Flt-3,PDGFR-β,c-Kit和EGFR)。对接分析表明,化合物42可以与c-Met形成三个氢键 结构与活性之间的关系研究表明,在苯环的4位上,水溶性更强的环状叔胺和吸电子基团有助于抗肿瘤活性。
  • The Chemistry of 2<i>H</i>-3,1-Benzoxazine-2,4(1<i>H</i>)-dione (Isatoic Anhydride). 20<sup>1</sup>. Synthesis and Wittig Reactions of Dimethyl (4-Oxo-1,4-dihydro-Quinolin-2-yl)methanephosphonates
    作者:Gary M. Coppola
    DOI:10.1055/s-1988-27474
    日期:——
    Isatoic anhydrides react with dilithiated 2-oxoalkanephosphonates to give dimethyl (4-oxo-1,4-dihydroquinolin-2-yl)methanephosphonates 5. These phosphonates undergo a Horner reaction with aldehydes to produce 2-(1-alkenyl)-4(1H)- quinolinones 10 in good yields.
    异阿托酸酐与二锂化的2-氧代烷基膦酸酯反应,生成二甲基(4-氧代-1,4-二氢喹啉-2-基)甲基膦酸酯5。这些膦酸酯经过Horner反应与醛反应,以良好的产率生成2-(1-烯基)-4(1H)-喹啉酮10。
  • Antiviral quinolinone compounds
    申请人:Schering Corporation
    公开号:US05179107A1
    公开(公告)日:1993-01-12
    Compounds useful as antiviral agents against DNA containing viruses, such as herpes group viruses, are disclosed. The compounds are selected from the group consisting of: ##STR1## and their pharmaceutically acceptable salts and solvates. Pharmaceutical compositions containing compounds represented by Formula 1.0 are disclosed. Also disclosed are methods of treating a viral infection using compounds represented by Formula 1.0. A process for making compounds of Formula 1.0 from the appropriate 3-oximino-quinolin-2,4(1H)-dione (Formula 2.5) is also disclosed. The process comprises reductively hydrolyzing an appropriate 3-oximino-quinolin-2,4(1H)-dione (Formula 2.5) in a mixture with a hydrogenation catalyst and an acidic solvent mixture.
    揭示了作为抗DNA含病毒(如疱疹病毒组)的抗病毒剂的有用化合物。这些化合物选自以下组合物:##STR1##及其药学上可接受的盐和溶剂。揭示了含有代表Formula 1.0的化合物的药物组合物。还揭示了使用代表Formula 1.0的化合物治疗病毒感染的方法。还揭示了一种从适当的3-氧基亚喹啉-2,4(1H)-二酮(Formula 2.5)制备Formula 1.0化合物的过程。该过程包括在含有氢化催化剂和酸性溶剂混合物的混合物中还原水解适当的3-氧基亚喹啉-2,4(1H)-二酮(Formula 2.5)。
  • TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES
    申请人:Sircar Jagadish
    公开号:US20080139551A1
    公开(公告)日:2008-06-12
    treatment of a variety of disorders, including the treatment of pathological conditions associated with tumor necrosis factor alpha. The inhibitors of tumor necrosis factor alpha have the following structures: including stereoisomers, pharmaceutically acceptable salts, and solvates thereof, wherein substituents are as defined herein. Compositions containing an inhibitor of tumor necrosis factor alpha in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
    治疗各种疾病,包括与肿瘤坏死因子α相关的病理条件的治疗。肿瘤坏死因子α的抑制剂具有以下结构:包括立体异构体、药用可接受的盐和溶剂,其中取代基如本文所定义。还提供了含有肿瘤坏死因子α抑制剂与药用可接受载体结合的组合物,以及使用方法。
查看更多